News

Company News: Micromet Achieves Milestone under BiTE Antibody Collaboration with Bayer Schering Pharma

Micromet, Inc. (NASDAQ: MITI) a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that it has achieved a milestone under its collaboration agreement with Bayer Schering Pharma AG.  The milestone was triggered by Micromet’s achievement of pre-clinical proof of concept for a BiTE antibody for the treatment of solid tumors. For more information, please read the complete press release

Company News: SuppreMol Receives U.S. Orphan Drug Designation for SM101

SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that the FDA’s Office of Orphan Products Development has granted Orphan Drug Designation (ODD) for SuppreMol’s lead product SM101, a recombinant human soluble Fcγ receptor IIb, for the treatment of Idiopathic Thrombocytopenic Purpura (ITP).

At present, SM101 is in a Phase Ib/IIa clinical study in ITP, with results expected in early 2011. For the same indication, the molecule has already been granted Orphan Medicinal Product Designation in Europe by the EU Commission in 2007. Further details are available on the company’s website.

Company News: 365 Energy Installs First Coulomb ChargePoint Networked Charging Stations for Ireland’s Electric Supply Board

European Market Expansion of 365 Energy Gains Further Momentum

365 Energy has announced the installation of the first Coulomb ChargePoint® Networked Charging Stations in Dublin, Ireland. The charging stations were provided to Ireland’s Electric Supply Board (ESB) and recently went live in the Dublin city centre. The installation of these charging stations is only the beginning of Ireland’s nationwide e-mobility infrastructure initiative. The ESB is planning to install charging stations in homes, on-street and along motor-ways throughout Ireland so that electric cars can be powered at a wide range of accessible venues.

For more information, please click here

Company News: SuppreMol Initiates Phase Ib/IIa Clinical Trial With Its Lead Candidate SM101

SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced the initiation of a Phase Ib/IIa clinical trial with its lead product SM101 in Idiopathic Thrombocytopenic Purpura (ITP) in Europe. For further details on the trial and the compound, please see the complete press release.

In a Phase Ia trial in 48 healthy volunteers started in April 2009, no SM101-associated adverse reactions have been observed. Detailed results of this study will be published soon.

1 138 139 140 143